Retatrutide vs Tirzepatide vs Semaglutide Compared

Three of the most-discussed metabolic research peptides — compared by mechanism, trial outcomes, and what makes each one distinct.

May 13, 202610 min read

The incretin agonist family at a glance

Semaglutide, tirzepatide, and retatrutide represent three generations of incretin receptor agonists. Each adds another receptor target, and each has shown progressively larger effects in published trials.

Semaglutide is a single agonist (GLP-1). Tirzepatide is a dual agonist (GIP + GLP-1). Retatrutide is a triple agonist (glucagon + GIP + GLP-1).

Receptor targets compared

Semaglutide → GLP-1 receptor only
Tirzepatide → GIP + GLP-1 receptors
Retatrutide → glucagon + GIP + GLP-1 receptors

Trial-program weight outcomes

In the STEP program, semaglutide 2.4 mg weekly produced an average ~14.9% body-weight reduction over 68 weeks. In SURMOUNT-1, tirzepatide 15 mg weekly produced ~22.5% reduction over 72 weeks. In published phase 2 data for retatrutide at 12 mg weekly, the reduction reached ~24.2% at 48 weeks.

These numbers come from peer-reviewed publications and describe research outcomes only.

Why glucagon agonism matters

Adding glucagon receptor activation to incretin agonism (as retatrutide does) increases energy expenditure and lipid oxidation in addition to the satiety and glycemic effects of GLP-1/GIP. This is the proposed mechanism behind retatrutide's outsized weight-reduction signal in early trials.

Side-effect profiles in trials

All three peptides shared a gastrointestinal side-effect profile in trials — nausea, diarrhea, and constipation, mostly during dose escalation. The frequency of GI events scaled with dose and with receptor coverage. Adverse events are documented in the published trial reports.

Dosing protocols studied

Semaglutide: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly titration
Tirzepatide: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg weekly titration
Retatrutide (phase 2): 0.5 → 2 → 4 → 8 → 12 mg weekly titration

Frequently asked questions

Which peptide produces the largest weight reduction in trials?

In published trial data, retatrutide showed the largest reductions, followed by tirzepatide, then semaglutide. The pattern correlates with the number of incretin receptors each peptide activates.

Are these peptides interchangeable?

No. Each peptide has a distinct receptor profile, dosing schedule, and side-effect curve. Substituting one for another in research outside published protocols is not supported by the literature.